Hot Features
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthal... Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1 | -1 | 10 | 10.615 | 9.37 | 4199479 | 9.77749066 | CS |
| 4 | 1.4 | 16.4705882353 | 8.5 | 10.615 | 8.071 | 3008953 | 9.15696802 | CS |
| 12 | 1.81 | 22.3733003708 | 8.09 | 10.615 | 7.86 | 3039533 | 9.07940928 | CS |
| 26 | -2.76 | -21.8009478673 | 12.66 | 13.03 | 6.3 | 4567797 | 9.23149996 | CS |
| 52 | 0.81 | 8.91089108911 | 9.09 | 16.44 | 6.3 | 3642685 | 10.37024496 | CS |
| 156 | 5.07 | 104.968944099 | 4.83 | 16.44 | 1.995 | 2217516 | 8.81451335 | CS |
| 260 | -4.79 | -32.6072157931 | 14.69 | 16.44 | 1.995 | 1700103 | 8.23084391 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.